Test directory: Teriflunomide (TDM), Serum

Ordering Code 5297
Test Name Teriflunomide (TDM), Serum
Preferred Specimen Serum
Preferred Container Plain (Red)
Other Specimen/Container Plasma in EDTA, K2 (Lavender)
Optimum Volume 1 mL
Handling Instructions Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial.
Transport Requirements Oahu: Refrigerated
Airline: Refrigerated
Specimen Stability Ambient: 30 Days
Refrigerated: 30 Days
Frozen: 24 Months
Rejection Criteria Gel barrier tube
Avail. Stat NO
Analytic Time 12 Days
Methodology High Performance Liquid Chromotography/Tandem Mass
Spectrometry (LC-MS/MS)
Reference Lab  National Medical Services, Inc.

Reference range(s)

The reference ranges listed below are valid on this date of June 29, 2025.
Component Age Male Norm Male Critical Low Male Critical High Female Norm Female Critical High Female Critical Low Units Add'l info
Teriflunomide (TDM) ALL ng/mL

Teriflunomide...
Teriflunomide is indicated for the treatment of patients with relapsing forms of multiple sclerosis
It takes approximately 3 months to reach steady-state concentrations

Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL

Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. THIS TEST IS NOT MEANT TO MONITOR THE
ELIMINATION OF TERIFLUNOMIDE IN WOMEN OF CHILDBEARING
POTENTIAL WHO DISCONTINUE TERIFLUNOMIDE. The drug carries a black box warning for hepatotoxicity and teratogenicity

See report.
Note1

Note1:


Teriflunomide is indicated for the treatment of patients with relapsing forms of multiple sclerosis
It takes approximately 3 months to reach steady-state concentrations

Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL

Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. THIS TEST IS NOT MEANT TO MONITOR THE
ELIMINATION OF TERIFLUNOMIDE IN WOMEN OF CHILDBEARING
POTENTIAL WHO DISCONTINUE TERIFLUNOMIDE. The drug carries a black box warning for hepatotoxicity and teratogenicity

See report..